BAIYUNSHAN PH (00874) has announced that its wholly-owned subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., has received the Drug Supplement Approval Notice from the National Medical Products Administration. The notice confirms that the Norepinephrine Bitartrate Injection (1ml:2mg) has passed the consistency evaluation for generic drug quality and therapeutic equivalence.

This approval marks a significant milestone for the company, as it validates the quality and efficacy of the product, aligning it with the standards set for generic drugs in the Chinese pharmaceutical market. The consistency evaluation is a critical step in ensuring that generic drugs meet the same rigorous standards as their branded counterparts, thereby enhancing patient access to affordable and reliable medications.

The successful completion of this evaluation is expected to strengthen the company's market position in the cardiovascular drug segment, where norepinephrine is widely used for the management of acute hypotension. It also underscores the company's commitment to maintaining high manufacturing standards and compliance with regulatory requirements.